Considering it was one of the pandemic's biggest market winners, Teladoc Health's (NYSE: TDOC) stock looks remarkably run-down right now. Over the last three years, its shares have seen their value fall by 50%, dramatically underperforming the market's gain of more than 40%. That's enough to make many investors start to look for the door -- but it's also the kind of dip that attracts bargain hunters and contrarians.

So is this company worth buying, or is Teladoc's time as a growth stock in the limelight now part of a quickly receding past? To get some more clarity on this topic, let's discuss a couple of arguments in favor of starting a position, and then two arguments in favor of selling or shorting the stock.

Teladoc's business model is to provide telemedicine services to its customers -- insurance companies, other businesses, and individuals. It collects subscription fees from its clients every month, and then uses the revenue to pay its clinicians and other staff.

Continue reading

Source Fool.com